Nicholas Butowski
SRN-101 is designed to destroys tumor cells while simultaneously activating the immune system to fight cancer. This is a first in human, single arm study to evaluate SRN-101 for the treatment of adults with recurrent high-grade glioma (rHGG) who are eligible for resection.
PRIMARY OBJECTIVES: I. To evaluate the safety and tolerability of intratumoral administration of SRN-101 in participants with recurrent high-grade glioma (rHGG) undergoing resection. II. To evaluate the biologic activity of SRN-101. EXPOLORATORY OBJECTIVES: I. To assess immunologic response to SRN-101. II. To identify potential pharmacodynamics biomarkers for SRN-101 activity. OUTLINE: Participants will receive a single administration of SRN-101 during real-time magnetic resonance imaging (MRI)-guided convection-enhanced delivery (CED), followed by non-investigational surgical resection 7…
Inclusion Criteria: 1. Male or female ≥ 18 years of age. 2. Participants have received at least one prior line of standard-of-care treatment for high-grade glioma (HGG). Specifically, participants have received prior surgery that resulted in histopathologic diagnosis followed by treatment with radiation alone and/or radiation plus temozolomide. 3. Participants with recurrent high-grade glioma (rHGG) for whom resection is planned, and with a lesion that is accessible to convection-enhanced delivery (CED) therapy. Eligible tumor types include central nervous system (CNS) World Health Organizati…
Given Intratumoral
Perform blood work
Undergo surgery
Undergo imaging
Arctuva estimate
Verify or correct the compensation shown for this listing.